ImmunoVec is a biotechnology company with a novel platform using DNA-loaded polymeric nanoparticles to precisely reprogram cells in patients, offering the potential to reset the immune system and transform treatment for life-threatening autoimmune diseases, solid tumors, and genetic disorders. The company’s proprietary platform combines synthetic, cell type-specific promoters across multiple delivery vehicles to enable precise and durable expression of therapeutic payloads within targeted cells. ImmunoVec is headquartered in Los Angeles.